Showing 15 posts of 19 posts found.


MSD announce new data from advanced renal cell carcinoma trial

June 8, 2021
Manufacturing and Production MSD, rcc

Merk (MSD) has announced positive data from its Phase III Clear/Keynote-581 trial on Keytruda (pembrolizumab) plus Lenvima (lenvatinib), and Lenvima …

FDA building

FDA approves AVEO’s kidney cancer treatment

March 11, 2021
Aveo, FDA, Kidney cancer, fotivda, rcc

The FDA has approved AVEO Oncology’s FOTIVDA drug for the treatment of adults with relapsed or refractory advanced renal cell …


MSD’s Keytruda combo therapy significantly improves survival in advanced renal cell carcinoma

February 18, 2019
Sales and Marketing Cancer, MSD, Merck Sutent, Pfizer, inlyta, keytruda, oncology, rcc, renal cell carcinoma

Merck & Co’s Keytruda (pembrolizumab) in combination with Pfizer’s Inlyta (axitinib) significantly extended the lives of those with advanced renal …

Scotland approves first-line treatment for advanced kidney cancer

July 9, 2018
Sales and Marketing Cancer, Scotland, fotivda, rcc, tivozanib

The Scottish Medicines Consortium has approved the use of EUSA Pharma’s Fotivda (tivozanib) as a first-line treatment for people with …

Pfizer image

SMC approves Inlyta

November 13, 2013
Sales and Marketing Pfizer, SMC, Sutent, inylta, rcc

Pfizer’s kidney cancer drug Inlyta has been approved by the drugs watchdog in Scotland, making it the only country in …


Double approval for Pfizer cancer drugs

September 6, 2012
Sales and Marketing CML, Cancer, Glivec, Pfizer, axitinib, rcc

 Two cancer drugs from Pfizer have been approved, one in Europe for kidney cancer and another in the US for …

Pfizer image

Torisel-Avastin combo fails in kidney cancer

August 13, 2012
Research and Development, Sales and Marketing R&D, Sutent, Torisel, avastin, failure, rcc

Combining Pfizer’s Torisel and Roche’s Avastin does not increase survival rates for advanced kidney cancer patients. This is according to …

Nexavar image

Torisel fails in head-to-head study with Nexavar

May 16, 2012
Research and Development, Sales and Marketing Bayer, Nexavar, Pfizer, Torisel, inlyta, rcc

Pfizer’s kidney cancer drug Torisel has failed to best Bayer’s Nexavar in a head-to-head trial.  The Phase III study was …

FDA approves Pfizer cancer drug Inlyta

January 30, 2012
Sales and Marketing Nexavar, Pfizer, Sutent, rcc, renal cell carcinoma

Pfizer’s kidney cancer drug Inlyta has gained US approval for second line treatment for the disease. Inlyta (axitinib) is now …

Pfizer HQ

Pfizer files new kidney cancer drug

June 2, 2011
Sales and Marketing Nexavar, Pfizer, rcc

Pfizer has filed its kidney cancer drug axitinib in the EU after impressive head-head- trials with Bayer’s Nexavar. Pfizer is …

Pfizer’s cancer drug meets end points in head-to-head study

May 20, 2011
Research and Development, Sales and Marketing Pfizer, axitinib, rcc

Pfizer’s investigational cancer drug axitinib significantly increased survival in kidney cancer patients when compared to Bayer’s standard treatment Nexavar. New …

Astellas to commercialise new kidney cancer drug in Europe

February 21, 2011
Sales and Marketing Astellas, Aveo Pharmaceuticals, Cancer, Kidney cancer, rcc, renal cell carcinoma, tivozanib

Astellas and Aveo Pharmaceuticals are to commercialise Aveo’s investigational kidney cancer drug tivozanib in Europe and the US. Aveo is …

GSK’s patient access scheme for Votrient sways NICE

December 24, 2010
Sales and Marketing GSK, GlaxoSmithKline, NICE, Votrient, pazopanib, rcc, renal cell carcinoma

NICE has recommended GlaxoSmithKline’s kidney cancer drug Votrient in final draft guidance after the pharma company offered to implement a …

The renal cell carcinoma market: Votrient to challenge Sutent’s lead

November 25, 2010
Sales and Marketing GSK, GlaxoSmithKline, Pfizer, Sutent, Votrient, rcc, renal cell carcinoma

After decades of no new medicines emerging to treat renal cell carcinoma, no fewer than five new drugs were approved …

GSK tipped to lead kidney cancer market

July 1, 2010
Sales and Marketing Kidney cancer, Patorma, Votrient, rcc

GlaxoSmithKline’s kidney cancer drug Votrient has been forecast as a future leader in a marketplace currently dominated by Pfizer. Analysts …

Latest content